333.17744g Prescribing and dispensing certain hormonal contraceptives; promulgation of rules; self-screening risk assessment tool.
585 words·~3 min read·
/mi/chapter-333/333-17744gA research copy — for the controlling text, always check the official state or federal source. Not legal advice.
333.17744g Prescribing and dispensing certain hormonal contraceptives; promulgation of rules; self-screening risk assessment tool.
Sec. 17744g.
(1)Subject to the rules promulgated under this section, a pharmacist may issue a prescription for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, or a vaginal ring hormonal contraceptive to an individual, regardless of the individual's age and regardless of whether the individual has evidence of a previous prescription from a prescriber for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, or a vaginal ring hormonal contraceptive.
(2)By 18 months after the effective date of the amendatory act that added this section, the department, in consultation with the board, shall promulgate rules to implement this section. The rules must establish a standard procedure for issuing a prescription for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, and a vaginal ring hormonal contraceptive under this section. The rules must also prohibit a pharmacist from issuing a prescription for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, or a vaginal ring hormonal contraceptive to an individual described in subsection
(1)if the individual has not completed the self-screening risk assessment tool developed under subsection
(3)and must require that a pharmacist comply with all of the following:
(a)Complete a training program that is approved by the board for issuing a prescription for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, or a vaginal ring hormonal contraceptive.
(b)Provide the self-screening risk assessment tool that is developed under subsection
(3)to an individual described in subsection
(1)before issuing a prescription for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, or a vaginal ring hormonal contraceptive to the individual.
(c)Upon issuing a prescription for the hormonal contraceptive patch, self-administered hormonal contraceptive, emergency contraceptive, or vaginal ring hormonal contraceptive to an individual described in subsection (1), refer the individual to the individual's primary care physician, or if the individual does not have a primary care physician, to another licensed health professional that the pharmacist considers appropriate.
(d)Provide an individual described in subsection
(1)with a written record of the hormonal contraceptive patch, self-administered hormonal contraceptive, emergency contraceptive, or vaginal ring hormonal contraceptive for which the individual is issued the prescription and advise the individual to consult with a physician or other licensed health professional.
(e)If an individual described in subsection
(1)has not had a physical examination in the previous 12 months, refer the individual to the individual's primary care provider for a physical examination after issuing a prescription for the hormonal contraceptive patch, self-administered hormonal contraceptive, emergency contraceptive, or vaginal ring hormonal contraceptive to the individual.
(f)Dispense the hormonal contraceptive patch, self-administered hormonal contraceptive, emergency contraceptive, or vaginal ring hormonal contraceptive to an individual described in subsection
(1)as soon as practicable after issuing the prescription for the hormonal contraceptive patch, self-administered hormonal contraceptive, emergency contraceptive, or vaginal ring hormonal contraceptive to the individual, or transmit the prescription to another pharmacy of the individual's choice if authorized pursuant to rules promulgated by the department.
(3)The department, in consultation with the board, shall by rule develop a self-screening risk assessment tool to be used by an individual who is seeking a prescription for a hormonal contraceptive patch, a self-administered hormonal contraceptive, an emergency contraceptive, or a vaginal ring hormonal contraceptive under this section.
History: Add. 2024, Act 242 , Eff. Apr. 2, 2025
Popular Name: Act 368